Stufenadaptierte Therapie des Status epilepticus

Adam Strzelczyk; Felix Rosenow

doi:10.1055/a-0657-8254

Neurologie up2date, Table of Contents

Neurologie up2date 2018; 1(01): 67-79
DOI: 10.1055/a-0657-8254

Neurologische Notfall- und Intensivmedizin

Georg Thieme Verlag KG Stuttgart · New York

Stufenadaptierte Therapie des Status epilepticus

Adam Strzelczyk

,

Felix Rosenow

Abstract

All articles of this category

Der Status epilepticus ist ein wichtiger neurologischer Notfall, der einer sofortigen medizinischen Behandlung bedarf. Eine Vielzahl von Benzodiazepinen, Antikonvulsiva und Anästhetika wird zur akuten prä- und intrahospitalen Behandlung des Status epilepticus eingesetzt. Da eine lange Statusdauer mit dem Outcome negativ korreliert, ist eine schnelle, ausreichend dosierte und an die Statusschwere angepasste Behandlung essenziell, um das funktionelle Outcome zu optimieren und die Mortalität zu reduzieren.

Schlüsselwörter

Epilepsie - Benzodiazepine - Levetiracetam - Lacosamid - Valproat - Narkose

Full Text

References

Literatur
1 Knake S, Rosenow F, Vescovi M. et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001; 42: 714-718 doi:10.1046/j.1528-1157.2001.01101.x
2 Strzelczyk A, Ansorge S, Hapfelmeier J. et al. Costs, length of stay, and mortality of super-refractory status epilepticus: A population-based study from Germany. Epilepsia 2017; 58: 1533-1541 doi:10.1111/epi.13837
3 Kortland LM, Knake S, von Podewils F. et al. Socioeconomic Outcome and quality of life in adults after status epilepticus: a multicenter, longitudinal, matched case-control analysis from Germany. Frontiers Neurol 2017; 8: 507 doi:10.3389/fneur.2017.00507
4 Kortland LM, Alfter A, Bahr O. et al. Costs and cost-driving factors for acute treatment of adults with status epilepticus: A multicenter cohort study from Germany. Epilepsia 2016; 57: 2056-2066 doi:10.1111/epi.13584
5 Rossetti AO, Logroscino G, Milligan TA. et al. Status Epilepticus Severity Score (STESS): a tool to orient early treatment strategy. J Neurol 2008; 255: 1561-1566 doi:10.1007/s00415-008-0989-1
6 Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology 1993; 43: 483-488
7 Rosenow F. Status epilepticus im Erwachsenenalter. In: Diener HC, Weimar C. Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme; 2012: 48-57
8 Trinka E, Cock H, Hesdorffer D. et al. A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015; 56: 1515-1523 doi:10.1111/epi.13121
9 Beuchat I, Novy J, Rossetti AO. Newer Antiepileptic Drugs for Status Epilepticus in Adults: Whatʼs the Evidence?. CNS Drugs 2018; 32: 259-267 doi:10.1007/s40263-018-0509-5
10 Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134: 2802-2818 doi:10.1093/brain/awr215
11 Alldredge BK, Gelb AM, Isaacs SM. et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345: 631-637 doi:10.1056/NEJMoa002141
12 Kapur J, Macdonald RL. Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 1997; 17: 7532-7540
13 Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol 2006; 5: 246-256 doi:10.1016/S1474-4422(06)70374-X
14 Kadel J, Bauer S, Hermsen AM. et al. Use of emergency medication in adult patients with epilepsy: a multicentre cohort study from Germany. CNS Drugs 2018; 32: 771-781 doi:10.1007/s40263-018-0544-2
15 Semmlack S, Yeginsoy D, Spiegel R. et al. Emergency response to out-of-hospital status epilepticus: A 10-year observational cohort study. Neurology 2017; 89: 376-384 doi:10.1212/WNL0000000000004147
16 Strzelczyk A, Kay L, Kellinghaus C. et al. Concepts for prehospital and initial in-hospital therapy of status epilepticus. Neurology International Open 2017; 1: E217-E223 doi:10.1055/s-0043-110486
17 Silbergleit R, Durkalski V, Lowenstein D. et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366: 591-600 doi:10.1056/NEJMoa1107494
18 Kay L, Reif PS, Belke M. et al. Intranasal midazolam during presurgical epilepsy monitoring is well tolerated, delays seizure recurrence, and protects from generalized tonic-clonic seizures. Epilepsia 2015; 56: 1408-1414 doi:10.1111/epi.13088
19 Treiman DM, Meyers PD, Walton NY. et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792-798 doi:10.1056/NEJM199809173391202
20 Kellinghaus C, Stogbauer F. Treatment of status epilepticus in a large community hospital. Epilepsy Behav 2012; 23: 235-240 doi:10.1016/j.yebeh.2011.12.020
21 Alvarez V, Januel JM, Burnand B. et al. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia 2011; 52: 1292-1296 doi:10.1111/j.1528-1167.2011.03056.x
22 Knake S, Gruener J, Hattemer K. et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiat 2008; 79: 588-589 doi:10.1136/jnnp.2007.130260
23 Rossetti AO, Bromfield EB. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav 2006; 8: 651-654 doi:10.1016/j.yebeh.2006.01.006
24 Strzelczyk A, Zollner JP, Willems LM. et al. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia 2017; 58: 933-950 doi:10.1111/epi.13716
25 Perrenoud M, Andre P, Alvarez V. et al. Intravenous lacosamide in status epilepticus: Correlation between loading dose, serum levels, and clinical response. Epilepsy Res 2017; 135: 38-42 doi:10.1016/j.eplepsyres.2017.05.007
26 Strzelczyk A, Steinig I, Willems LM. et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals. Epilepsy Behav 2017; 70: 177-181 doi:10.1016/j.yebeh.2017.03.028
27 Strzelczyk A, Kay L, Bauer S. et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia 2018; 59: 1549-1556 doi:10.1111/epi.14476
28 Kalss G, Rohracher A, Leitinger M. et al. Intravenous brivaracetam in status epilepticus: A retrospective single-center study. Epilepsia 2018;
29 Nicolas JM, Hannestad J, Holden D. et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 2016; 57: 201-209 doi:10.1111/epi.13267
30 Sutter R, Marsch S, Fuhr P. et al. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology 2014; 82: 656-664 doi:10.1212/WNL0000000000000009
31 Marchi NA, Novy J, Faouzi M. et al. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med 2015; 43: 1003-1009 doi:10.1097/CCM0000000000000881
32 Sutter R, De Marchis GM, Semmlack S. et al. Anesthetics and outcome in status epilepticus: a matched two-center cohort study. CNS Drugs 2017; 31: 65-74 doi:10.1007/s40263-016-0389-5
33 Alvarez V, Lee JW, Westover MB. et al. Therapeutic coma for status epilepticus: Differing practices in a prospective multicenter study. Neurology 2016; 87: 1650-1659 doi:10.1212/WNL0000000000003224
34 Hofler J, Rohracher A, Kalss G. et al. (S)-ketamine in refractory and super-refractory status epilepticus: retrospective study. CNS Drugs 2016; 30: 869-876 doi:10.1007/s40263-016-0371-2
35 Stojanova V, Rossetti AO. Oral topiramate as an add-on treatment for refractory status epilepticus. Acta Neurol Scand 2012; 125: e7-e11 doi:10.1111/j.1600-0404.2011.01562.x
36 Strzelczyk A, Kortland LM, Knake S. et al. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand 2015; 132: 435-439 doi:10.1111/ane.12403
37 Rohracher A, Kalss G, Neuray C. et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: A single-center audit of 30 patients. Epilepsia 2018;
38 Kellinghaus C, Berning S, Stogbauer F. Use of oxcarbazepine for treatment of refractory status epilepticus. Seizure 2014; 23: 151-154 doi:10.1016/j.seizure.2013.11.002
39 Jones S, Pahl C, Trinka E. et al. A protocol for the inhospital emergency drug management of convulsive status epilepticus in adults. Pract Neurol 2014; 14: 194-197 doi:10.1136/practneurol-2013-000712